ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Brincidofovir for Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid Organ Transplant Recipients

J. Londeree1, R. Garro1, R. Romero2, R. George1, P. Winterberg1, R. Liverman3, A. Serluco3, S. Shin1, I. Yildirim4

1Pediatric Nephrology, Emory, Atlanta, GA, 2Pediatric Hepatology and Gastroenterology, Emory, Atlanta, GA, 3Pharmacy, Children's Healthcare of Atlanta, Atlanta, GA, 4Pediatric Infectious Disease, Emory, Atlanta, GA

Meeting: 2020 American Transplant Congress

Abstract number: C-182

Keywords: Adenoviruses, Kidney transplantation, Liver transplantation, Pediatric

Session Information

Session Name: Poster Session C: All Infections (Excluding Kidney & Viral Hepatitis)

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Brincidofovir (BCV) is an investigational antiviral drug with potency against Human Adenovirus (HAdV). We describe four cases of disseminated HAdV infection treated with (BCV) among pediatric solid organ transplant (SOT) patients.

*Methods: We retrospectively reviewed 4 cases of severe disseminated HAdV infection, which occurred between 2018 and 2019, in a tertiary pediatric transplant center. HAdV infection was defined as a positive HAdV PCR from a clinical specimen. Baseline clinical characteristics, disease course, treatment, and outcomes were reviewed.

*Results: Four pediatric SOT patients (2 kidney, 1 dual kidney/liver and 1 liver) ranging in age from 9 months to 19 years were diagnosed with HAdV infection (Table 1). Patients presented with varied symptoms from 12 to 912 days post-transplant. Peak HAdV viral load ranged from 37,000 to >1,000,000 copies/mL. All patients had disseminated disease with evidence of graft involvement and varying degrees of acute kidney injury (AKI) (Table 2) making them candidates for BCV therapy over cidofovir to avoid nephrotoxicity. Three out of four patients received cidofovir prior to conversion to BCV. IRB approved compassionate use of BCV was dosed at 2 mg/kg (max 100 mg) twice weekly PO along with reduced immunosuppression. Resolution of symptoms and HAdV viremia was seen at a mean of 21.5 days (range 15-32) of therapy. All patients had resolution of AKI with a return to baseline creatinine after therapy.

*Conclusions: Though HAdV infection in pediatric SOT patients is uncommon, a subset of patients experience severe disease complicated by graft dysfunction. Although supportive care and decreased immunosuppression remain the cornerstone of therapy, BCV was well tolerated and efficacious in our series of patients. Further research is needed to better understand risk factors for HAdV infection and treatment options to improve patient outcomes.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Londeree J, Garro R, Romero R, George R, Winterberg P, Liverman R, Serluco A, Shin S, Yildirim I. Brincidofovir for Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/brincidofovir-for-treatment-of-disseminated-human-adenovirus-infection-in-pediatric-solid-organ-transplant-recipients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences